TC-2216
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H17N3 |
| Molar mass | 203.283 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and is being researched for the treatment of anxiety and depression.[1]
References[edit]
- ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| 5-HT1AR agonists | |
|---|---|
| GABAAR PAMs |
|
| Gabapentinoids (α2δ VDCC blockers) | |
| Antidepressants |
|
| Sympatholytics (Antiadrenergics) |
|
| Others | |
| |
| nAChRs |
| ||||
|---|---|---|---|---|---|
| Precursors (and prodrugs) | |||||
Retrieved from "https://en.wikipedia.org/w/index.php?title=TC-2216&oldid=797544739"